Loxo Oncology raises $33 mln in Series A financing
Loxo Oncology said Thursday that it has closed $33 million in Series A financing. Founding investor Aisling Capital and new investor OrbiMed Advisors participated in the round. In addition to the funding, Also, Loxo Oncology has formed a board of directors, which includes Steven Elms and Dr. Dov Goldstein, managing partner and partner at Aisling Capital, respectively, and Dr. David Bonita, private equity partner at OrbiMed Advisors. Loxo Oncology is a a biopharmaceutical company focused on targeted cancer therapies.
3 October 2013•3 mins read
